This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria

This study has been withdrawn prior to enrollment.
(Funding problem; trial abandoned.)
Information provided by:
Chinese University of Hong Kong Identifier:
First received: July 27, 2007
Last updated: July 31, 2015
Last verified: January 2009
Glomerulonephritis and renal failure represent one of the most life-threatening manifestations of systemic lupus erythematosus (SLE). Although immunosuppressive therapy is often effective for the treatment of acute lupus nephritis, a significant proportion of patients show persistent proteinuria after resolution of the acute nephritic process, and develop progressive renal failure. There is preliminary evidence that calcitriol and other vitamin D analogs can reduce proteinuria in patients with chronic kidney diseases. The investigators plan to conduct a randomized control study to evaluate the safety and efficacy of calcitriol in the treatment of SLE patients with persistent proteinuria. Sixty patients with clinically quiescent SLE and persistent proteinuria despite conventional therapy will be recruited. They will be treated with calcitriol for 48 weeks. Proteinuria, renal function, lupus disease activity, serum and urinary inflammatory markers will be monitored. This study will explore the potential anti-proteinuric and immunomodulating effects of calcitriol in the treatment of SLE, which is a common and life threatening disease in young adults.

Condition Intervention Phase
Systemic Lupus Erythematosus Nephritis Proteinuria Drug: Calcitriol Drug: Multivitamin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria

Resource links provided by NLM:

Further study details as provided by Chinese University of Hong Kong:

Primary Outcome Measures:
  • change in proteinuria [ Time Frame: one year ]

Secondary Outcome Measures:
  • Secondary end points include risk of lupus flare, change in renal function, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, serum and urinary inflammatory markers. [ Time Frame: one year ]

Enrollment: 0
Study Start Date: May 2008
Study Completion Date: September 2009
Primary Completion Date: September 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: treatment group
Patients will receive calcitriol at a fixed dose of 1 mcg twice weekly.
Drug: Calcitriol
Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
Active Comparator: control group
Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
Drug: Multivitamin
Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • aged 18-65 years
  • clinical quiescent SLE for at least 12 weeks
  • baseline SLEDAI score <= 4
  • history of biopsy-proven lupus nephritis
  • estimated glomerular filtration rate 15 to 60 ml/min/1.73m2
  • proteinuria > 1 g/day (or proteinuria > 1 g/g-Cr) in 2 consecutive samples within 12 weeks despite ACE inhibitor or angiotensin receptor blocker for at least 3 months
  • on maintenance dose of prednisolone < 10 mg/day, with or without other immunosuppressive medications
  • corrected serum calcium level < 2.45 mmol/l
  • willingness to give written consent and comply with the study protocol

Exclusion Criteria:

  • Pregnancy, lactating or childbearing potential without effective method of birth control
  • Severe gastrointestinal disorders that interfere with their ability to receive or absorb oral medication
  • History of malignancy, including leukemia and lymphoma within the past 2 years
  • Systemic infection requiring therapy at study entry
  • Any other severe coexisting disease such as, but not limited to, chronic liver disease, myocardial infarction, cerebrovascular accident, malignant hypertension
  • History of drug or alcohol abuse within past 2 years
  • Participation in any previous trial on vitamin D analogue
  • Patients receiving treatment of vitamin D and/or its analogue for other medical reasons within the past 4 weeks. Patients who are taking multivitamin supplement that contains vitamin D could be enrolled after 4 weeks of wash out period by changing to a preparation that has no vitamin D.
  • On other investigational drugs within last 30 days
  • History of a psychological illness or condition such as to interfere with the patient's ability to understand the requirement of the study
  • History of non-compliance
  • Known history of sensitivity or allergy to vitamin D analogs
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00508898

Sponsors and Collaborators
Chinese University of Hong Kong
Principal Investigator: Cheuk-Chun Szeto, MD Chinese University of Hong Kong
  More Information

Responsible Party: SZETO, Cheuk Chun, The Chinese University of Hong Kong Identifier: NCT00508898     History of Changes
Other Study ID Numbers: CRE-2007.261-T
Study First Received: July 27, 2007
Last Updated: July 31, 2015

Keywords provided by Chinese University of Hong Kong:
lupus nephritis
chronic kidney diseases

Additional relevant MeSH terms:
Lupus Erythematosus, Systemic
Lupus Nephritis
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Urination Disorders
Urologic Diseases
Urological Manifestations
Signs and Symptoms
Kidney Diseases
Calcium Channel Agonists
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Vasoconstrictor Agents
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents processed this record on August 17, 2017